STOCK TITAN

Enlivex Therapeutics Ltd - ENLV STOCK NEWS

Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.

Overview of Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd (ENLV) is an Israel-based, clinical-stage biopharmaceutical company specializing in the field of immunotherapy. The company focuses on developing an allogeneic, off-the-shelf cell therapy designed to rebalance dysregulated immune responses by reprogramming macrophages to a homeostatic state. This innovative approach is applied across several therapeutic areas including severe inflammatory conditions, osteoarthritis, and various autoimmune and infectious diseases. Early clinical investigations target severe sepsis, complications in hematopoietic stem cell transplants, and inflammatory joint diseases such as psoriatic arthritis and knee osteoarthritis.

Clinical Development and Mechanism of Action

At the heart of Enlivex's research is Allocetra, a cell therapy candidate developed to reset abnormal, non-homeostatic macrophages. Unlike traditional treatments, Allocetra utilizes the body’s own natural regulatory mechanisms to modulate immune responses. This strategy not only addresses immediate clinical symptoms but also tackles the underlying pathophysiological processes of immune dysregulation. The company has successfully initiated multiple investigator-sponsored trials and randomized controlled studies to assess the therapy’s safety profile and potential clinical benefits. Ongoing research in conditions such as osteoarthritis and psoriatic arthritis highlights the broad potential of Allocetra to offer transformative treatment alternatives where existing therapies have limited efficacy.

Position in the Immunotherapy Landscape

Enlivex Therapeutics operates in a highly competitive and innovative segment of the life sciences industry. By focusing on macrophage reprogramming, the company distinguishes itself from other immunotherapy and cell therapy firms. Its strategy of using allogeneic cells enables off-the-shelf availability, thereby potentially reducing production complexities and shortening time-to-treatment. This unique value proposition underlines its relevance in contemporary immunotherapeutic paradigms while also addressing significant unmet medical needs in various clinical settings.

Key Business Areas and Research Focus

  • Macrophage Reprogramming: Employing its proprietary cell therapy to reset dysregulated immune cells.
  • Clinical Trials: Advancing early-phase trials in conditions like severe sepsis, graft versus host disease, and inflammatory joint diseases, which serve as proof-of-concept studies for the therapy’s mechanism of action.
  • Innovative Cell Therapy: Developing universal, off-the-shelf treatments with the potential to overcome limitations associated with autologous cell therapies.
  • Market Differentiation: Focusing on rare and difficult-to-treat conditions where conventional therapies have shown limited success.

Scientific Rationale and Industry Terminology

The scientific framework behind Enlivex's approach revolves around concepts such as immune homeostasis and macrophage plasticity. By targeting the inflammatory cascade and enabling macrophages to revert to their native, balanced state, Allocetra is posited as a potentially transformative intervention in areas where an exaggerated immune response leads to tissue damage and systemic complications. The rigorous clinical assessments being conducted are designed to quantify endpoints like pain reduction, improved joint function, and overall patient well-being using established indices and statistical methodologies.

Competitive Landscape and Investment Considerations

Within the biopharmaceutical industry, Enlivex stands out by focusing on a mechanism of action that taps into the regulatory potential of the immune system, thereby offering a counterpoint to therapies that rely solely on immunosuppression. This strategy positions the company in a unique niche that blends the principles of cellular therapy with precision immunomodulation. Investors and industry analysts typically examine parameters such as the safety profile observed in early-stage trials, the scalability of the off-the-shelf approach, and the breadth of the potential market for inflammatory and autoimmune indications. The transparent and phased clinical development strategy underscores the company’s commitment to rigorous scientific validation and adherence to regulatory standards.

Conclusion

Enlivex Therapeutics Ltd is a focused and innovative clinical-stage company working to bridge key gaps in the treatment of complex immune-mediated conditions. By emphasizing a cell therapy that rebalances the immune system through macrophage reprogramming, the company continues to build a robust clinical pipeline aimed at addressing some of the most challenging therapeutic areas in modern medicine. With its clear scientific rationale, structured developmental approach, and commitment to high-quality clinical research, Enlivex remains a noteworthy subject for in-depth investment research and clinical analysis.

Rhea-AI Summary

Enlivex Therapeutics announced the issuance of U.S. Patent No. 10,927,343 for AllocetraTM, its macrophage reprogramming immunotherapy. This patent enhances intellectual property protection for treating autoimmune and inflammatory diseases, including Crohn's disease and ulcerative colitis. While focusing on critical diseases like sepsis and COVID-19, preclinical data suggest AllocetraTM may provide immune rebalancing for unmet medical needs. This development aims to establish a novel therapy mechanism targeting life-threatening conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics (NASDAQ: ENLV) announced the closure of a public offering of 2,296,107 ordinary shares priced at $20.00 each, generating approximately $45.92 million in gross proceeds. The offering was managed by H.C. Wainwright & Co., which also received a 30-day option to purchase an additional 344,416 shares. Enlivex plans to allocate the net proceeds towards clinical, regulatory, and research activities, as well as potential acquisitions. The company operates under a shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics (NASDAQ: ENLV) announced an increase in its public offering to 2,296,107 ordinary shares, priced at $20.00 each, due to high demand. The offering is expected to close around February 12, 2021, pending customary closing conditions. Gross proceeds are projected to be approximately $46 million, which will be utilized for clinical, regulatory, and research activities, among other corporate purposes. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.08%
Tags
none
Rhea-AI Summary

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced an underwriting agreement with H.C. Wainwright & Co. to issue 500,000 ordinary shares at $20.00 each, aiming for gross proceeds of $10 million. The offering is set to close around February 12, 2021, subject to customary conditions. The underwriter also has a 30-day option for an additional 75,000 shares. Proceeds will fund clinical and regulatory activities, potential acquisitions, and general corporate purposes. This offering falls under a previously filed shelf registration statement with the SEC, providing liquidity for future endeavors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.08%
Tags
-
Rhea-AI Summary

Enlivex Therapeutics announced positive results from a Phase II clinical trial of AllocetraTM in severe and critical COVID-19 patients. The trial, which treated 16 patients, showed 0% mortality at day-28 and 87.5% recovery rate. The average hospitalization duration post-treatment was 5.3 days. Based on these outcomes, the trial was concluded early to expedite regulatory submissions. Enlivex is optimistic about AllocetraTM's potential in treating severe COVID-19 and other conditions associated with dysfunctional macrophages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced its participation at the H.C. Wainwright BioConnect 2021 Virtual Conference, with on-demand presentations available starting January 11, 2021, at 6:00 a.m. ET. The company's lead product, AllocetraTM, is an off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state, targeting diseases like solid cancers and sepsis. This innovative approach aims to address significant unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
conferences
Rhea-AI Summary

Enlivex Therapeutics has reported promising results from a Phase Ib trial of AllocetraTM for severe sepsis. Comparing 10 treated patients to 37 matched controls revealed significant benefits: zero mortality in the treated group versus 27% in controls, a 58% reduction in ICU stay (4.7 vs. 11.1 days), and no increase in organ-failure among treated patients. The trial confirms AllocetraTM as a safe and potentially effective treatment option for sepsis, a condition currently lacking effective therapies. Full data is available on medRxiv.org.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a new patent from the China National Intellectual Property Administration for its immunotherapy product, AllocetraTM. This patent strengthens the Company's intellectual property rights in China by covering methods, uses, and pharmaceutical compositions associated with AllocetraTM, aimed at treating life-threatening conditions such as sepsis and COVID-19. Enlivex focuses on developing immunotherapies for unmet medical needs, particularly in organ dysfunction and cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.31%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced positive interim results from its Phase II clinical trial of AllocetraTM in severe and critical COVID-19 patients. Out of eight treated patients, seven fully recovered and were discharged within an average of 4.7 days, while one patient improved from critical to moderate/severe. The treatment was well tolerated with no serious adverse events reported. The trial is part of a multi-center study aimed at evaluating AllocetraTM alongside standard care for the target patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.85%
Tags
clinical trial covid-19
Rhea-AI Summary

Enlivex Therapeutics has announced a positive clinical outcome for a 70-year-old patient with erosive osteoarthritis treated with Allocetra™. After five weekly infusions, the patient showed significant improvement, including a 93% reduction in CRP levels and no need for re-hospitalization over 24 months. This case marks a notable achievement in treating a rare disease with no effective options. Allocetra™ is also undergoing clinical studies for other conditions, including COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
none

FAQ

What is the current stock price of Enlivex Therapeutics (ENLV)?

The current stock price of Enlivex Therapeutics (ENLV) is $1.01 as of April 2, 2025.

What is the market cap of Enlivex Therapeutics (ENLV)?

The market cap of Enlivex Therapeutics (ENLV) is approximately 20.7M.

What is the core focus of Enlivex Therapeutics Ltd?

Enlivex Therapeutics Ltd is focused on developing an allogeneic cell therapy aimed at rebalancing immune responses through macrophage reprogramming, addressing conditions such as severe sepsis and inflammatory joint diseases.

How does Allocetra work as a therapeutic option?

Allocetra works by reprogramming non-homeostatic macrophages into their natural, balanced state, thereby helping to modulate the immune system and potentially reduce damaging inflammatory responses.

In which therapeutic areas is Enlivex conducting clinical trials?

Enlivex is investigating Allocetra in various clinical settings including severe sepsis, conditions associated with graft versus host disease, osteoarthritis, and psoriatic arthritis, among other inflammatory conditions.

What differentiates Enlivex from other companies in the immunotherapy space?

Enlivex differentiates itself by focusing on a unique mechanism of action through macrophage reprogramming, which offers a novel and off-the-shelf solution compared to traditional immunosuppressive or autologous cell therapies.

Why is immune rebalancing important in treating inflammatory diseases?

Immune rebalancing is crucial because it targets the underlying dysregulation in the immune system, potentially mitigating tissue damage and systemic complications that occur when the body’s natural response becomes excessive or misdirected.

What are the advantages of an off-the-shelf cell therapy product like Allocetra?

An off-the-shelf cell therapy can be made readily available, reducing the complexity and waiting times associated with autologous therapies. This approach also has the potential for scalable manufacturing and consistent quality control.

How does the company ensure the safety and efficacy of its therapy?

The safety and efficacy of Allocetra are evaluated through multiple phases of clinical trials, including rigorous safety run-ins and randomized, placebo-controlled studies that measure endpoints such as pain reduction and functional improvement.

What kind of investor or research interest does Enlivex attract?

Enlivex attracts interest from investors and analysts focused on innovative biopharmaceuticals, particularly those looking at next-generation cell therapies and immunomodulatory treatments that address significant unmet medical needs.
Enlivex Therapeutics Ltd

Nasdaq:ENLV

ENLV Rankings

ENLV Stock Data

20.74M
19.34M
5.59%
22.15%
0.52%
Biotechnology
Healthcare
Link
Israel
Ness Ziona